DealsMay 19, 2026, 04:32 PM
Eton Pharma acquires U.S. commercialization rights for IMPAVIDO®
AI Summary
Eton Pharmaceuticals, Inc. announced it has entered into a supply and distribution agreement for the exclusive U.S. commercialization rights to IMPAVIDO® (miltefosine) from an affiliate of Knight Therapeutics, Inc. IMPAVIDO® is the first and only FDA-approved oral therapy for visceral, cutaneous, and mucosal leishmaniasis, a rare and potentially life-threatening parasitic disease. The agreement, which takes effect on September 26, 2026, expands Eton's growing portfolio of orphan therapies and reinforces its focus on rare disease commercialization.
Key Highlights
- Eton Pharmaceuticals secured exclusive U.S. commercialization rights for IMPAVIDO® (miltefosine) from Knight Therapeutics.
- IMPAVIDO® is the first and only FDA-approved oral therapy for visceral, cutaneous, and mucosal leishmaniasis.
- The exclusive U.S. commercialization rights take effect on September 26, 2026.
- IMPAVIDO® is an orphan drug indicated for adults and adolescents over 12 years and weighing more than 30 kg.
- The transaction adds another 2026 product launch to Eton's portfolio.
- IMPAVIDO® has been commercially available in the United States since 2016.
- Eton's portfolio now includes ten commercial rare disease products.
Price Impact
More from ETON